EPIRUS Biopharmaceuticals

📍 Boston, United States🗓 Founded 2013👥 4 employees💰 Last funded Jul 2014
Biotechnology🌐 epirusbiopharma.com
Website LinkedIn
EPIRUS Biopharmaceuticals (Nasdaq:EPRS) is a pure-play biosimilar company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs). EPIRUS' goal is to improve global patient access to important, cost-effective medicines. The company's current pipeline of biosimilar product candidates includes: BOW015 (infliximab, reference biologic Remicade®) currently marketed outside the U.S. and in an ongoing global Phase 3 study for registration in Europe and North America; BOW050 (adalimumab, reference biologic Humira®); BOW070 (tocilizumab, reference biologic Actemra®); BOW080 (eculizumab, reference biologic Soliris®); BOW090 (ustekinumab, reference biologic STELARA®); and BOW100 (golimumab, reference biologic SIMPONI®). The reference products for these candidates together generated approximately $29.2 billion in global sales for 2014, according to EvaluatePharma®. EPIRUS has established multiple partnerships to support its regulatory and commercialization efforts in global markets.
2
Total investors
2
Early stage
0
Mid stage
0
Late stage
2013
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in EPIRUS Biopharmaceuticals?
EPIRUS Biopharmaceuticals has 2 investors on record on gritt.io, including 2 early-stage backers.
When did EPIRUS Biopharmaceuticals last raise funding?
The most recent investment in EPIRUS Biopharmaceuticals recorded on gritt.io was in July 2014.
When was EPIRUS Biopharmaceuticals founded?
EPIRUS Biopharmaceuticals was founded in 2013.
What industry is EPIRUS Biopharmaceuticals in?
EPIRUS Biopharmaceuticals operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is EPIRUS Biopharmaceuticals based?
EPIRUS Biopharmaceuticals is headquartered in Boston, United States.